• PDB80 REDUCING COSTS AND IMPROVING OUTCOMES BY REDUCING MEDICAL ERRORS- A COMPARISON OF EXPERTS WITH PROBABLISTIC LABORATORY ERROR DETECTION IN A POPULATION OF PRE-DIABETICS

    May 1, 2008, 00:00

  • PRS40 ABSENCE OF CONTROLLER DRUG USE AMONG ASTHMATIC PATIENTS AT RISK OF ASTHMA ATTACK

    May 1, 2008, 00:00

  • AC2 PATTERNS OF DIABETES MEDICATION AND TEST ADHERENCE IN A MEDICAID DISEASE MANAGEMENT PROGRAM

    May 1, 2008, 00:00

  • PDB26 ECONOMIC EVALUATION OF THE TREATMENT WITH QUINAGOLIDE IN PATIENTS WITH HYPERPROLACTINAEMIA, TUMOUR REDUCTION

    May 1, 2008, 00:00

  • PND22 THE COST OF DISABILITY AND MEDICALLY-RELATED ABSENTEEISM AMONG EMPLOYEES WITH MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PGI5 COST-EFFECTIVENESS OF NATALIZUMAB IN CROHNS DISEASE PATIENTS WHO HAVE FAILED ANTI-TNF ALPHA THERAPY

    May 1, 2008, 00:00

  • PMS30 EFFECTS OF 12-HOUR, EXTENDED-RELEASE HYDROCODONE/ACETAMINOPHEN ON PAIN-RELATED WORK PRODUCTIVITY- A SUBANALYSIS FROM A 56-WEEK OPEN-LABEL STUDY

    May 1, 2008, 00:00

  • PHC8 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN SLOVAKIA

    May 1, 2008, 00:00

  • PCV67 RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PIH14 ECONOMIC EVALUATION OF ATOSIBAN VERSUS BETA-MIMETICS IN THE TREATMENT OF PRETERM LABOUR IN GERMANY

    May 1, 2008, 00:00

  • PHP9 UNITED STATES PHYSICIANS AND IN-OFFICE DRUG ADMINISTRATION-THE CONCEPT OF 'INCIDENT-TO' SERVICES

    May 1, 2008, 00:00

  • PDB23 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE I DIABETES PATIENTS- A CANADIAN PERSPECTIVE

    May 1, 2008, 00:00

  • PHP12 ASSOCIATION BETWEEN DIRECT-TO-CONSUMER ADVERTISING (DTCA) AND DRUG UTILIZATION INTHE U.S. MEDICAID MARKET FOR SELECTED DRUG CLASSES

    May 1, 2008, 00:00

  • PMC47 EFFICIENCY OF HYBRID APPLICATIONS OF EXACT COVARIATE MATCHING AND PROPENSITY SCORE

    May 1, 2008, 00:00

  • PHP69 THE PRESCRIBING OF CHINESE HERBAL PRODUCTS IN TAIWAN-A CROSS-SECTIONAL ANALYSIS OFTHE NATIONAL HEALTH INSURANCE REIMBURSEMENT DATABASE

    May 1, 2008, 00:00

  • PIH4 COMPARISON OF MEN AGE 21 YEARS AND OLDER WITH AND WITHOUT ERECTILE DYSFUNCTION ON CONCOMITANT PRESCRIPTION DRUG, COMORBID CONDITIONS, SMOKING STATUS AND BMI

    May 1, 2008, 00:00

  • PIN5 INTEREST OF MULTI-CRITERIA MODELING APPROACH IN ASSESSMENT OF YELLOW FEVER EPIDEMIC RISK

    May 1, 2008, 00:00

  • PHP25 TOWARD HIGH PERFORMANCE PHARMACARE' SYSTEMS- A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES

    May 1, 2008, 00:00

  • CASE 2 DRUG ELUTING STENTS-AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES

    May 1, 2008, 00:00

  • PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES- DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?

    May 1, 2008, 00:00

  • PSS20 COST-EFFECTIVENESS OF TOBRADEX VERSUS ZYLET FOR THE TREATMENT OF BLEPHAROKERATOCONJUNCTIVITIS

    May 1, 2008, 00:00

  • PCV93 LIFETIME MEDICAL EXPENDITURES AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES

    May 1, 2008, 00:00

  • PHP47 ASSESSMENT OF NATIONAL MEDICARE PART D ESTIMATED ANNUAL COSTS FOR 2007 AND 2008 USING A PATIENT COHORT

    May 1, 2008, 00:00

  • PIN20 PHARMACOECONOMICS OF CHRONIC HEPATITIS BAND HEPATITIS C

    May 1, 2008, 00:00

  • PMC30 A REVIEW AND CRITIQUE OF METHODS FOR MEASURING TEMPORARY HEALTH STATES IN COST-UTILITY ANALYSES

    May 1, 2008, 00:00

  • PR1 VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURINGTREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD

    May 1, 2008, 00:00

  • PDB36 HEALTH SERVICE COSTS AND RESOURCE UTILIZATION AMONG MANAGED CARE ENROLLEES WITH GOUT AND RENAL DISEASE

    May 1, 2008, 00:00

  • PMC8 A CONCEPTUAL FRAMEWORKTO ANALYZE A DISEASES WORKPLACE IMPACT ON AN EMPLOYER

    May 1, 2008, 00:00

  • PCN80 COMPARISON OF STANDARD GAMBLE UTILITIES AND VISUAL ANALOG SCALEVALUES IN AN OVARIAN CANCER PATIENT AND ONCOLOGIST STUDY OF CANCER TREATMENT PREFERENCES

    May 1, 2008, 00:00

  • PCV79 PHYSICIAN CHARACTERISTICS ASSOCIATED WITH STROKE RELATED OUTPATIENT CARE UTILIZATION- ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA 2000-2005

    May 1, 2008, 00:00

  • PCN7 ANALYSIS OF MASTECTOMY IN BREAST CANCER TREATMENT

    May 1, 2008, 00:00

  • PIN35 RESOURCE UTILIZATION IN UNITED KINGDOM DIAGNOSED HCV PATIENTS

    May 1, 2008, 00:00

  • PGI28 IMPORTANT FACTORS WHEN CONSIDERING TREATMENT FOR ULCERATIVE COLITIS

    May 1, 2008, 00:00

  • Validity of the Health Profile-Types of the Spanish Child Health and Illness Profile-Adolescent Edition (CHIP-AE)

    May 1, 2008, 00:00

  • PSY35 PREVALENCE OF METABOLIC SYNDROME AND ITS IMPACT ON HEALTH CARE RESOURCE UTILIZATION

    May 1, 2008, 00:00

  • PSS23 PROACTIVE USE OFTACROLIMUS 0.03 OINTMENT IN CHILDREN WITH MODERATE OR SEVERE ATOPIC DERMATITIS-OUTCOMES AND COST

    May 1, 2008, 00:00

  • PCN68 HOUSEHOLD INCOME AS A PREDICTOR OF PSYCHOLOGICAL WELL-BEING AMONG LONG-TERM COLORECTAL CANCER SURVIVORS

    May 1, 2008, 00:00

  • PHP1 EFFECT OF PRESCRIPTION COPAY ON MEDICATION UTILIZATION

    May 1, 2008, 00:00

  • PRS14 BENEFITS FROM IMPROVED ASTHMA CARE IN FINLAND 1987-2005 ASSESSED WITH ANALYSIS OF COMPREHENSIVE SOCIETAL COST AND BEHAVIOUR OF COST DRIVERS

    May 1, 2008, 00:00

  • PUK22 ASSESSING PATIENT DESCRIPTIONS OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND PERSPECTIVES ON TREATMENT OUTCOMES FOR THE DEVELOPMENT OF A NEW LUTS PATIENT REPORTED OUTCOME TOOL

    May 1, 2008, 00:00

  • PCV8 BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. ...

    May 1, 2008, 00:00

  • PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING

    May 1, 2008, 00:00

  • PMH50 MEDICATION ADHERENCE, ETHNICITY, ANDTHE INFLUENCE OF MULTIPLE PSYCHOSOCIAL AND FINANCIAL BARRIERS IN VETERANS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PCN69 QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN RECEIVING TREATMENT FOR PROSTATE CANCER

    May 1, 2008, 00:00

  • A Modeled Economic Evaluation Comparing Atomoxetine with Stimulant Therapy in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder in the United Kingdom

    May 1, 2008, 00:00

  • PDB77 INVOLVEMENT OF LAYVOLUNTEERS IN TRAINING ON SELF-MANAGEMENT OF PATIENTS WITH DIABETES IN THE UNITED KINGDOM-COST IMPLICATIONS

    May 1, 2008, 00:00

  • PSS44 USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    May 1, 2008, 00:00

  • PSS24 TRENDS IN EPISODE OF TREATMENT COSTS OF ACNE ACROSS THE UNITED STATES

    May 1, 2008, 00:00

  • PIN47 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH CHRONIC HEPATITIS C RELATED COMPLICATIONS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSS28 DISTANCE VISUAL ACUITY AS A MEASURE OF VISION FUNCTION-INSIGHT INTO THE ASSOCIATION OF ETDRS LETTERS AND SELF-REPORT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)

    May 1, 2008, 00:00

  • PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA

    May 1, 2008, 00:00

  • PDB5 COMPARISON OF CLINICAL EFFECTIVENESS AND SAFETY OF GLULISINE VERSUS INSULIN LISPRO, ASPART AND REGULAR HUMAN INSULIN IN PATIENTS WITH TYPE I AND 2 DIABETES

    May 1, 2008, 00:00

  • PSY50 PHYSICIANS INTENTIONS TO MEASURE BODY MASS INDEX IN CHILDREN AND ADOLESCENTS-ATHEORY OF REASONED ACTION MODEL

    May 1, 2008, 00:00

  • PSS17 ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030 ON THE EYES OF PATIENTS WHO UNDERWENT TO LASIK LASER EYE SURGERY AT THE IMMEDIATELY POST-OPERATIVE TIME

    May 1, 2008, 00:00

  • PMC25 SENSITIVITY ANALYSIS FOR PROPENSITY SCORE MATCHING

    May 1, 2008, 00:00

  • MD7 DIFFERENTIALTAKE-UP OFTHE MEDICARE PART D PRESCRIPTION DRUG BENEFIT

    May 1, 2008, 00:00

  • PHP34 PRINCIPAL COMPONENTS ANALYSIS OF DRUG UTILIZATION AND EXPENDITURETRENDS FOR MAJORTHERAPEUTIC CLASSES IN U.S. MEDICAID PROGRAMS

    May 1, 2008, 00:00

  • PDB14 BUDGET IMPACT OF ADDING FIXED-DOSE COMBINATION OF PIOGLITAZONE PLUS GLIMEPIRIDETO A FORMULARY PLAN OVERATHREE-YEARTIME FRAME

    May 1, 2008, 00:00

  • PND9 COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA- A US PERSPECTIVE

    May 1, 2008, 00:00

  • PCN83 KNOWLEDGE OF THE BRAZILIAN POPULATION ABOUT COLORECTAL CANCER

    May 1, 2008, 00:00

  • PCN77 A SYSTEMATIC REVIEW OF BREAST CANCER UTILITY WEIGHTS

    May 1, 2008, 00:00

  • An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy

    May 1, 2008, 00:00

  • PDB35 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PDB57 CONTENT DEVELOPMENT FORA NEW INSTRUMENT TO ASSESS PATIENT AND PARENT PREFERENCE FOR GROWTH HORMONE REPLACEMENT THERAPY DELIVERY DEVICES

    May 1, 2008, 00:00

  • PMH81 EXAMINING THE PERCEIVED BURDEN OF PRIOR AUTHORIZATION OF PSYCHOTHERAPEUTICS AMONG TEXAS MEDICAID PRESCRIBERS

    May 1, 2008, 00:00

  • PMH25 HEALTH CARE USE AND COSTS OF PATIENTS WITH 'PURE OBSESSIVE-COMPULSIVE DISORDER' VERSUS 'PURE DEPRESSION'- 9-YEAR (1997-2006), LARGE-SCALE, RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID ADULT ENROLLEES

    May 1, 2008, 00:00

  • PCV82 EVALUATION OF THE EFFECT OF ACUTE DECOMPENSATED HEART FAILURE GUIDELINES IN COMMUNITY HOSPITALS

    May 1, 2008, 00:00

  • PCASE1 GCSF- SAVING COSTS WITHOUT SAVING QUALITY OF CARE. A UNIMED VITORIA HEALTH INSURANCE EXPERIENCE

    May 1, 2008, 00:00

  • PDB25 COSTS AND EFFECTIVENESS OF INSULIN VS. ROSIGLITAZONE IN TYPE 2 DIABETES AFTER METFORMIN MONOTHERAPY FAILURE

    May 1, 2008, 00:00

  • PSY52 INADEQUATE GASTROPROTECTION AMONG NEW CHRONIC USERS OFTRADITIONAL NSAIDS IN THE NETHERLANDS

    May 1, 2008, 00:00

  • PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS

    May 1, 2008, 00:00

  • AC1 THEASSOCIATION BETWEEN IMPROVEMENTS IN DRUG ADHERENCE AND SHORT-TERM SERVICE UTILIZATION AND COSTS IN A MEDICAID POPULATION

    May 1, 2008, 00:00

  • PIN42 DESIGNING AND TESTING A HIV-PATIENT SATISFACTION SURVEY FOR A COMPARITIVE ANALYSIS OF MAIL-ORDER PHARMACYVS. COMMUNITY PHARMACY SERVICES

    May 1, 2008, 00:00

  • PDB9 TYPE 2 DIABETES IN YOUTH- 2002 AND 2006 PREVALENCE AND OBESITY IN A PRIMARY CARE SETTING

    May 1, 2008, 00:00

  • PUK6 FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER-A COST-EFFECTIVENESS CASE STUDY OF SWEDEN

    May 1, 2008, 00:00

  • PND19 THE ECONOMIC IMPACT OF ACUTE MEDICATION OVERUSE AMONG PATIENTS WITH MIGRAINE OR HEADACHE- A MANAGED CARE PERSPECTIVE

    May 1, 2008, 00:00

  • PND11 TRIPTANS FOR ACUTE MIGRAINE- A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES

    May 1, 2008, 00:00

  • PCV19 RESIDUAL DYSLIPIDEMIA ON SIMVASTATIN- POPULATION MODELING OF OPTIMAL LIPID VALUE ACHIEVEMENT WITH ADDED EXTENDED-RELEASE NIACIN VERSUS EZETIMIBE

    May 1, 2008, 00:00

  • PMH9 RETENTION RATES FOR ORAL AND DEPOT ANTIPSYCHOTIC MEDICATIONS OVER ONE YEAR IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • PDB58 ASSOCIATION BETWEEN THE DIABETES-39 (DM-39)ASA PATIENT REPORTED OUTCOME (PRO) AND HBAIC IN A CLINICAL TRIAL INVOLVING INSULIN THERAPY

    May 1, 2008, 00:00

  • PDB64 PHYSICIAN PRACTICE SPECIALTY AND TYPES OF ANTI-DIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES- ARE THEY ASSOCIATED?-A LARGE NATIONAL OBSERVATIONAL STUDY IN A MANAGED CARE SETTING

    May 1, 2008, 00:00

  • PMH41 COST UTILITY OF EEG BIOMARKERS FOR PERSONALIZED TREATMENT OF MAJOR DEPRESSION

    May 1, 2008, 00:00

  • PIN27 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FORTREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PMH23 A COMPARISION OF HEALTH CARE UTILIZATION AND COST OF CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER TREATED WITH ATYPICAL ANTIPSYCHOTIC MONOTHERAPYVERSUS MOOD STABILIZER MONOTHERAPY

    May 1, 2008, 00:00

  • PUK2 LONGITUDINAL DECLINE OF RENAL FUNCTION IN HYPERTENSIVE VETERANS

    May 1, 2008, 00:00

  • PMH12 TREATMENT OUTCOMES OF RISPERIDONE LONG ACTING INJECTION (RLAI) IN SCHIZOPHRENIA- 18-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN CZECH REPUBLIC AND SLOVAKIA

    May 1, 2008, 00:00

  • MH4 TREATMENT COST AND COMORBIDITIES ASSOCIATEDWITH OBESITY AMONG CHILDREN ANDADOLESCENTSWITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PUK11 URETEROSCOPYAND SHOCKWAVE LITHOTRIPSY FOR TREATMENT OF URETERAL STONES IN TAIWAN- ECONOMIC EVALUATION

    May 1, 2008, 00:00

  • PCV44 RELATIONSHIP BETWEEN THE OBESITY PARADOX AND HEALTH CARE EXPENDITURES IN SUBJECTS WITH CARDIOVASCULAR DISEASE USING THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2008, 00:00

  • PSS22 THE ANNUAL COST OF BACTERIAL CONJUNCTIVITIS IN THE UNITED STATES- EVIDENCE FROM AN ECONOMIC MODELLING APPROACH

    May 1, 2008, 00:00

  • PCV45 ECONOMIC IMPACT OF STROKE-RELATED COMORBID CONDITIONS ON THE TREATMENT OF STROKE- AN ANALYSIS OF MEDICARE BENEFICIARIES IN THE UNITED STATES

    May 1, 2008, 00:00

  • PHP68 CHARACTERISTICS OF RISK-SHARING SCHEMES IN EUROPE

    May 1, 2008, 00:00

  • PHP26 RESEARCH AND MARKETING COMPLEMENTARITY IN PHARMACEUTICAL FIRMS- EMPIRICAL EVIDENCE

    May 1, 2008, 00:00

  • PCN3 EFFECTIVENESS OF BORTEZOMIB IN MULTIPLE MYELOMA- PRELIMINARY RESULTS FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY

    May 1, 2008, 00:00

  • MD8 THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ONTHE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY

    May 1, 2008, 00:00

  • PMH20 A COST-BENEFIT ANALYSIS OF HIGHER MEDICATION COPAYMENTS IN VETERANS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PCN94 PREDICTORS OF TREATMENT CHOICE IN HIGH RISK AND METASTATIC MELANOMA- EVIDENCE FROM LINKED ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE CLAIMS DATA

    May 1, 2008, 00:00

  • PHC11 A SYSTEMATIC REVIEW OF STUDIES ON QUALITY OF LIFE IN ANIMALS

    May 1, 2008, 00:00

  • PCN36 COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN

    May 1, 2008, 00:00

  • PDB10 OBESITY IS MORE PREVALENT AMONG ABORIGINALS WITH DIABETES AS COMPARED TO ALL CANADIANS WITH DIABETES

    May 1, 2008, 00:00

  • PCN55 A COST-UTILITY ANALYSIS OF FULVESTRANT IN TREATING RECURRENT METASTATIC BREAST CANCER

    May 1, 2008, 00:00

  • PCV33 LONG-TERM REDUCTION OF CARDIOVASCULAR EVENTS AND COST-EFFECTIVENESS OF DIFFERENT STATINS AND DOSES IN MEXICO

    May 1, 2008, 00:00

  • PDB31 COST-EFFECTIVENESS OF DETEMIRVERSUS NPH FORTYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN PORTUGAL

    May 1, 2008, 00:00

  • PCN82 PATIENT-REPORTED OUTCOMES IN ELDERLY VS. YOUNG PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH SORAFENIB VS. PLACEBO

    May 1, 2008, 00:00

  • PHP51 COMPARISONS OF RELATIVE RISKS OF SERIOUS COMORBIDITIES AMONG EMPLOYEES WITH AND WITHOUT INSOMNIA, GERD, HEPATITIS C, MULTIPLE SCLEROSIS, AND CHRONIC CONSTIPATION

    May 1, 2008, 00:00

  • MD4 IMPACT OF THE MEDICARE MODERNIZATION ACT OF 2003 ON PART B DRUG USE AND SPENDING- A CASE STUDY OF BIOLOGICALS FOR RHEUMATOID ARTHRITIS

    May 1, 2008, 00:00

  • PMH49 EARLY DISCONTINUATION ONTREATMENT AND ITS CONSEQUENCES IN PATIENTS TREATED WITH VENLAFAXINE OR ESCITALOPRAM

    May 1, 2008, 00:00

  • PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2C) VERSUS CAPECITABINE ONLY (C-ONLY)

    May 1, 2008, 00:00

  • PUK12 COST-MINIMIZATION ANALYSIS OF EVEROLIMUS FOR KIDNEY TRANSPLANTATION IN BRAZIL

    May 1, 2008, 00:00

  • PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

    May 1, 2008, 00:00

  • PMH31 A PHARMACOECONOMIC ANALYSIS OF SCHIZOPHRENIC PATIENTS SWITCHING FROM BRANDED TO GENERIC RISPERIDONE INVOLVING A POSSIBLE COMPLIANCE LOSS

    May 1, 2008, 00:00

  • OM4 LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE

    May 1, 2008, 00:00

  • PRS24 CEILING EFFECTS AND DISCRIMINATION OF TREATMENT BENEFIT FOR PATIENTS WITH LOWER SYMPTOM SEVERITY- MEASUREMENT OF HEALTH UTILITIES IN ALLERGIC RHINITIS

    May 1, 2008, 00:00

  • PSY55 DIAGNOSIS ANDTREATMENT FLOWS FOR MORBIDLY OBESE PATIENTS VISITING PHYSICIAN OFFICES IN THE US

    May 1, 2008, 00:00

  • PCV27 COST EFFECTIVENESS STUDIES IN HEART FAILURE- AN UPDATE OF THE LITERATURE

    May 1, 2008, 00:00

  • PDB42 COST OF ILLNESS STUDY OF TYPE 2 DIABETES MELLITUS IN LATIN AMERICA

    May 1, 2008, 00:00

  • PCV64 IMPACT OF STATIN STEP CARE PROGRAM ON PATIENT COMPLIANCE

    May 1, 2008, 00:00

  • PDB73 NON-INJECTABLE INSULIN-TO PAY OR NOT TO PAY?

    May 1, 2008, 00:00

  • PSY25 ECONOMIC IMPACT AND CONSERVATION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG)THROUGHTHERAPEUTIC SUBSTITUTION WITH ANTI-D IN PATIENTS WITH IDIOPATHICTHROMBOCYTOPENIA PURPURA (ITP) AT AN URBANTEACHING HOSPITAL IN STATEN ISLAND, NY

    May 1, 2008, 00:00

  • PCN64 CLINICAL AND DEMOGRAPHIC PREDICTORS OF QUALITY OF LIFE IN PROSTATE CANCER SURVIVORS

    May 1, 2008, 00:00

  • PCN51 DIRECT ECONOMIC BURDEN OF HIGH RISK AND METASTATIC MELANOMA- EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE

    May 1, 2008, 00:00

  • PDB65 COMPARISON OF FOUR HEALTH STATE PREFERENCE MEASURES AMONG PATIENTS ENROLLED IN THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES TRIAL

    May 1, 2008, 00:00

  • PSY53 HOSPITAL CHARGES AND COMORBIDITIES AMONG OBESE AND MORBIDLY OBESE PATIENTS

    May 1, 2008, 00:00

  • PMS31 TWO-YEAR LONGITUDINAL STUDY OF PERSISTENCE TO ANTI-TUMOR NECROSIS FACTOR TREATMENT AMONG RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2008, 00:00

  • PND1 PREVALENCE AND COSTS OF COMORBIDITIES AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS- AN ANALYSIS OFTHE AHRQ MAJOR AND SPECIFIC DIAGNOSTIC CATEGORIES

    May 1, 2008, 00:00

  • MH1 REAL WORLD ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND WEIGHT GAIN IN AN ADOLESCENT POPULATION

    May 1, 2008, 00:00

  • PMH73 INITIATION OF ATOMOXETINE VS. STIMULANTS FOR CHILDREN WITH ADHD IN MEDICAID SETTINGS

    May 1, 2008, 00:00

  • PDB63 AN ECONOMIC EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM FORADULT MEDICAID CLIENTS IN THE STATE OF COLORADO, UNITED STATES

    May 1, 2008, 00:00

  • DH1 FOLLOW-UPVISITS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER DURING INITIATION OF ANTIDEPRESSANT TREATMENT

    May 1, 2008, 00:00

  • PND42 THE DEVELOPMENT OF A PATIENT SATISFACTION INSTRUMENT FOR INSOMNIA-A PSYCHOMETRIC APPROACH

    May 1, 2008, 00:00

  • CASE 6 THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY INTHEACUTE CARE SETTING

    May 1, 2008, 00:00

  • PHP46 IMPACT OF A DRUG POLICY ON AVAILABILITY AND DRUG COST CONTAINMENT IN A TERTIARY CARE HOSPITAL- I0YEARS OF EXPERIENCE

    May 1, 2008, 00:00

  • PSS40 QUALITY OF LIFE AND PSYCHOLOGICAL PROBLEMS IN PATIENTS WITH ORAL MUCOSAL DISEASES

    May 1, 2008, 00:00

  • PIH7 BURDEN OF ILLNESS OF HYPERTENSION AMONG WOMEN USING MENOPAUSAL HORMONE THERAPY

    May 1, 2008, 00:00

  • PCN27 COST-EFFECTIVENESS ANALYSIS OF SCREENING SUBJECTS WITH DIFFERENT LEVELS OF RISK FOR HEPATOCELLULAR CARCINOMA IN TAIWAN

    May 1, 2008, 00:00

  • PCV42 COST-EFFECTIVENESS ANALYSIS OF EDUCATIONAL PREVENTIVE TECHNOLOGIES FOR PATIENTS WITH CARDIOVASCULAR DISEASES IN RUSSIA

    May 1, 2008, 00:00

  • PDB18 COMPARISON OF RESOURCES UTILIZATION (RU)AND COST IN DRUG NAVE TYPE 2 DIABETES (T2D) PATIENTS TREATED WITH ROSIGLITAZONE (RSG)VS. SULFONYLUREA (SU) MONOTHERAPY

    May 1, 2008, 00:00

  • PMH3 STATISTICAL ANALYSIS OF SIGNIFICANT VARIABLES IN DEALING WITH DRUG ABUSE INPATIENTS

    May 1, 2008, 00:00

  • PCV76 LONGITUDINAL ASSESSMENT OF THE CLINICAL UTILITY OF POINT-OF-CARE MEASUREMENT DEVICES FOR DETERMINING THE INTERNATIONAL NORMALIZED RATIO

    May 1, 2008, 00:00

  • PUK5 COST-EFFECTIVENESS OF CINECALCET IN THE TREATMENT OF SECONDARY HYPERPARATIROIDISM (SHPT)

    May 1, 2008, 00:00

  • PSY51 THE EFFECTS OF COMORBIDITY, PRESCRIPTION DRUG USE, AND MEDICAL UTILIZATION ON DULOXETINE INITIATION IN PATIENTS WITH FIBROMYALGIA

    May 1, 2008, 00:00

  • PSY4 THE BALANCE BETWEEN SEVERE CARDIOVASCULAR AND GASTROINTESTINAL EVENTS AMONG USERS OF SELECTIVE AND NON-SELECTIVE NON STEROIDAL ANTI-INFLAMMATORY DRUGS

    May 1, 2008, 00:00

  • PHP30 COST-EFFECTIVENESS ANALYSIS AND RETURN ON INVESTMENT OF HIGH COST PATIENTS MANAGEMENT PROGRAMWITHIN A PRIVATE HEALTH CARE PLAN IN BRAZIL

    May 1, 2008, 00:00

  • PIH8 COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVES

    May 1, 2008, 00:00

  • PHP19 EFFECT OF PRESCRIPTION DRUG COVERAGE ON HEALTH AMONG CHRONICALLY ILL ELDERLY POPULATION

    May 1, 2008, 00:00

  • PMH45 COST OF PSYCHIATRIC HOSPITALIZATIONS IN THE UNITED SSTATES IN 2006

    May 1, 2008, 00:00

  • PSY29 THE DIRECT AND INDIRECT COSTS OF OBESITY IN AN EMPLOYED POPULATION

    May 1, 2008, 00:00

  • PDB59 IMPACT OF DOCTORS INSTRUCTIONS ON LIFESTYLE BEHAVIORS AMONG DIABETES POPULATION IN USA

    May 1, 2008, 00:00

  • PCV17 PREDICTING CLINICAL OUTCOMES IN MIXED DYSLIPIDEMIA PATIENTS USING THE FRAMINGHAM RISK AND A NEW RISK EQUATION BASED ON A MANAGED CARE DATABASE- A VALIDATION APPROACH

    May 1, 2008, 00:00

  • PND47 ARE THERE GENDER AND ETHNIC DISPARITIES IN THE USE OF INSOMNIA PRESCRIPTIONS?

    May 1, 2008, 00:00

  • PCV37 BIATRIAL VERSUS RIGHT ATRIAL APPENDAGE PACING IN BRADYCARDIA TACHYCARDIA SYNDROME

    May 1, 2008, 00:00

  • PIN26 ECONOMIC EVALUATION OF SUNITINIBVS. INTERFERON-ALFA (IFN-ALFA) IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA

    May 1, 2008, 00:00

  • PND10 SWITCHING TO HIGH-DOSE HIGH-FREQUENCY INTERFERONS OR NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS- A COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PSY18 A COMPARATIVE COST-EFFECTIVENESS ANALYSIS ONTHE USE OF FLECTOR(r) PATCH (DICLOFENAC EPOLAMINE TOPICAL PATCH) 1.3) FOR THE TREATMENT OF ACUTE PAIN FOLLOWING INJURY

    May 1, 2008, 00:00

  • PCV91 PATIENT INSURANCE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA

    May 1, 2008, 00:00

  • PMH63 PATIENT REPORTED MEASURES AS QUALITY ASSURANCE TOOLS IN CNS CLINICAL TRIALS

    May 1, 2008, 00:00

  • WH1 EXPOSURETO CONTRAINDICATEDAND OTHER POTENTIALLY DANGEROUS MEDICATIONS DURING PREGNANCY-A POPULATION BASED STUDY IN ITALY

    May 1, 2008, 00:00

  • PHP77 EVALUATION OF THE IMPACT OF PATIENT SAFETY ACTIVITIES ON THE NUMBER OF VOLUNTARY INCIDENT REPORTS AT TEACHING HOSPITALS IN JAPAN

    May 1, 2008, 00:00

  • PCV74 THE IMPACT OF TARGETED MEMBER EDUCATION ON CHOICE OF PREFERRED STATIN THERAPY AFTER A FORMULARY CHANGE

    May 1, 2008, 00:00

  • CA3 A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA

    May 1, 2008, 00:00

  • PSY41 PATIENT- AND CAREGIVER-REPORTED PREFERENCES FOR CHARACTERISTICS OFTREATMENTS FOR HEMOPHILIA PATIENTS WITH INHIBITORS

    May 1, 2008, 00:00

  • PIH16 THE DIRECT COSTS OF INJURIOUS FALLS IN SENIORS

    May 1, 2008, 00:00

  • PRS1 COMPARISON OF THE EFFECTIVENESS OF ONE VERSUS TWO ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP). AN ANALISYS USING PROPENSITY SCORE.

    May 1, 2008, 00:00

  • PSS34 QUALITY OF LIFE IN PATIENTS WITH VITILIGO. USE OF SINGLE ITEM ANALYSIS

    May 1, 2008, 00:00

  • PCN42 THE ECONOMIC BURDEN OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES

    May 1, 2008, 00:00

  • PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA

    May 1, 2008, 00:00

  • PMH19 MONOTHERAPYWITH ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIAS CLINICAL REVIEW AND ECONOMIC EVALUATION OF FIRST TWELVE MONTHS OF TREATMENT

    May 1, 2008, 00:00

  • PSS48 HEALTH CARE COSTS INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00

  • CASE 3 REVIEWING ANDADAPTINGA LOCAL HEALTH TECHNOLOGY ASSESSMENT PROGRAMTO DEPARTMENTS WITHIN A CANADIAN HEALTH REGION

    May 1, 2008, 00:00

  • PCASE3 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENTS CASE STUDY OF BORTEZOMIB AT A MAJOR CANCER CENTER

    May 1, 2008, 00:00

  • PCV31 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR DIAGNOSIS OF DEEP VEIN THROMBOSIS

    May 1, 2008, 00:00

  • PCV32 COST-EFFECTIVENESS OF CLINICAL PHARMACY SERVICES ON HYPERLIPIDAEMIC MANAGEMENT IN A PUBLIC HOSPITAL OF HONG KONG

    May 1, 2008, 00:00

  • PCN47 IMPACT OF HIV INFECTION ON INVASIVE CERVICAL CANCER INCIDENCE AND TREATMENT COSTS IN SOUTH AFRICAN WOMEN

    May 1, 2008, 00:00

  • PHP21 CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION PROFILES IN THE ELDERLY-A CALIFORNIA QUALITY IMPROVEMENT ORGANIZATION (QIO) COLLABORATIVE EXPERIENCE

    May 1, 2008, 00:00

  • PSS33 INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE-THE BEAUTYQOL INITIATIVE

    May 1, 2008, 00:00

  • PCV69 CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX VERSUS VITAMIN K ANTAGONIST IN PATIENTS WITH ATRIAL FIBRILLATION

    May 1, 2008, 00:00

  • PCN76 IMPACT OF SILDENAFIL ON MARITAL AND SEXUAL ADJUSTMENT IN PATIENTS AND THEIR PARTNERS AFTER RADIOTHERAPY AND SHORT-TERM ANDROGEN SUPPRESSION FOR PROSTATE CANCER- ANALYSIS OF RTOG 0215

    May 1, 2008, 00:00

  • PCV78 INTERNATIONAL COMPARISON OF HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- RESULTS FROM THE ANTIPLATELETTREATMENT OBSERVATIONAL STUDY (APTOR)

    May 1, 2008, 00:00

  • PCN60 EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL ECONOMIC VARIABLES ON HEALTH CARE RESOURCE UTILIZATION AND EXPENDITURE FOR BREAST CANCER PATIENTS USING MEPS 2001

    May 1, 2008, 00:00

  • PMC22 A MODELTO EXAMINE THE EFFECT OF GUIDELINES ON OUTCOMES RESEARCH

    May 1, 2008, 00:00

  • PND25 EXPLORING THE RELATIONSHIP BETWEEN DIFFERENT DISPENSING SYSTEMS AND MEDICATION COMPLIANCE AND PERSISTENCY IN MULTIPLE SCLEROSIS PATIENTS USING PHARMACY CLAIMS DATA

    May 1, 2008, 00:00

  • PMS45 A TWO-YEAR LONGITUDINAL STUDY OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2008, 00:00

  • PHP44 SOURCES OF MEDICAL INFORMATION AND DEGREE OF TRUST PLACED IN THEM BY RUSSIAN DOCTORS

    May 1, 2008, 00:00

  • PDB79 USING DECISION ANALYTIC METHODS TO REDUCE COSTLY LABORATORY ERRORS- ATEST OF A PROBABILISTIC AUTOVERIFICATION SYSTEM

    May 1, 2008, 00:00

  • PUK21 THE PSYCHOMETRIC VALIDATION OF AN US ENGLISH SATISFACTION MEASURE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

    May 1, 2008, 00:00

  • PIH9 COST-EFFECTIVENESS ANALYSIS OF CONTRACEPTIVES AVAILABLE IN UNITED STATES

    May 1, 2008, 00:00

  • PCN74 WILL KNOWLEDGE OF GENETIC RISK FOR CANCER INFLUENCE QUALITY OF LIFE AND SCREENING BEHAVIOR? FINDINGS FROM A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • PUK1 CHRONIC KIDNEY DISEASE (CKD) AMONG INPATIENTS WITH REDUCED KIDNEY FUNCTION (RKF) ON HOSPITAL ADMISSION

    May 1, 2008, 00:00

  • PSY2 THE DEVELOPMENT OF A STANDARDIZED CLINICAL ALGORYTHMIC PREDICTOR OF WEIGHT LOSS AFTER BARIATRIC SURGERY- DATABASE ANALYSIS ENABLES EMPIRICAL AND STATISTICAL PREDICTION OFTHRESHOLD WEIGHT LOSS BY END OFTHIRD POST-OPERATIVE PHYSICIAN VIS ...

    May 1, 2008, 00:00

  • PHP22 MEDICARE SPENDING GROWTH FOR DIAGNOSTIC IMAGING AND ACCESS TO CARE

    May 1, 2008, 00:00

  • PRS35 A STATISTICAL LOOK AT COPD

    May 1, 2008, 00:00

  • PCN41 THE LIFETIME COST OF CERVICAL CANCER IN TAIWAN

    May 1, 2008, 00:00

  • PSY8 THE ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG PATIENTS OFTHE CAROLINA LUPUS STUDY EARLY INTHE COURSE OF DISEASE

    May 1, 2008, 00:00

  • Outcome Measurement in Clinical Genetics Services- A Systematic Review of Validated Measures

    May 1, 2008, 00:00

  • PMS12 COST-EFFECTIVENESS ANALYSIS OF ZOLEDRONIC ACID VERSUS RISEDRONATE FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURE IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    May 1, 2008, 00:00

  • PMH28 COST-EFFECTIVENESS OF ONCE-DAILY STIMULANT, NON-STIMULANT COMBINED STIMULANT/BEHAVIORAL THERAPY INTERVENTIONS IN THE TREATMENT OF ADHD IN CHILDREN

    May 1, 2008, 00:00

  • PND43 LEVEL OF SATISFACTION OF SPANISH MULTIPLE SCLEROSIS PATIENTS TREATED WITH A NEW FORMULATION OF AVONEX (INTERFERON BETA-1A 30 MCG INTRAMUSCULAR, ONCE WEEKLY, SOLUTION FOR INJECTION READY TO USE)

    May 1, 2008, 00:00

  • PMS41 UTILIZATION AND COSTS OF DRUGS AND OFFICE SERVICES AMONG RECIPIENTS OF MEDICAID WITH RHEUMATOID ARTHRITIS WITH VERSUS WITHOUT COMORBID DEPRESSION

    May 1, 2008, 00:00

  • Duration of Antipsychotic Drug Therapy in Real-World Practice- A Comparison with CATIE Trial Results

    May 1, 2008, 00:00

  • PRS7 COST-EFFECTIVENESS OF CICLESONIDE VERSUS FLUTICASONE IN THE TREATMENT OF PATIENTS WITH MILD, MODERATE, AND SEVERE ASTHMA

    May 1, 2008, 00:00

  • PCV3 SYSTEMATIC REVIEW OF NICARDIPINE IN NEUROVASCULAR CONDITIONS

    May 1, 2008, 00:00

  • PRS41 AVAILABILITY AND PRICE OF TWO INHALATION MEDICINES FOR TREATMENT OF ASTHMA IN DIFFERENT STATES OF INDIA

    May 1, 2008, 00:00

  • PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC)- A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES

    May 1, 2008, 00:00

  • PIH29 ESTIMATION OF TYPE AND NUMBER OF MEDICATION ERRORS IN LONG-TERM CARE

    May 1, 2008, 00:00

  • PMS25 ASSOCIATION BETWEEN OUT-OF-POCKET EXPENSES AND CLINICAL OUTCOMES. AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2008, 00:00

  • Cost-Effectiveness and Value of Information Analyses of Neuraminidase Inhibitors for the Treatment of Influenza

    Mar 1, 2008, 00:00

  • Costs Associated with Diffuse Large B-Cell Lymphoma Patient Treatment in a Canadian Integrated Cancer Care Center

    Mar 1, 2008, 00:00

  • Practical Guidelines for Economic Evaluations Alongside Equivalence Trials

    Mar 1, 2008, 00:00

  • Probabilistic Cost-Effectiveness Modeling of Different Breast Cancer Screening Policies in Slovenia

    Mar 1, 2008, 00:00

  • A Difficult Balancing Act- Policy Actors' Perspectives on Using Economic Evaluation to Inform Health-Care Coverage Decisions under the Universal Health Insurance Coverage Scheme in Thailand

    Mar 1, 2008, 00:00

  • Applying the Expectancy-Value Model to Understand Health Values

    Mar 1, 2008, 00:00

  • Estimating the Effect of Treatment Rate Changes When Treatment Benefits Are Heterogeneous- Antibiotics and Otitis Media

    Mar 1, 2008, 00:00

  • Assessing Productivity Loss and Activity Impairment in Severe or Difficult-to-Treat Asthma

    Mar 1, 2008, 00:00

  • Factors Affecting Health-Care Costs and Hospitalizations among Diabetic Patients in Thai Public Hospitals

    Mar 1, 2008, 00:00

  • Comparison of the Initial Hospitalization Costs between the Patients Treated with Dobutamine and the Patients Treated with Amrinone for Acute Decompensated Heart Failure in a Japanese Institute

    Mar 1, 2008, 00:00

  • Equivalence of Electronic and Paper-and-Pencil Administration of Patient-Reported Outcome Measures- A Meta-Analytic Review

    Mar 1, 2008, 00:00

  • Cost-Effectiveness Study Comparing Cefoperazone-Sulbactam to a Three-Drug Combination for Treating Intraabdominal Infections in an Indian Health-Care Setting

    Mar 1, 2008, 00:00

  • A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore

    Mar 1, 2008, 00:00

  • Cost-Effectiveness of Rosuvastatin in the Prevention of Ischemic Heart Disease in Portugal

    Mar 1, 2008, 00:00

  • Reviewer Acknowledgment

    Mar 1, 2008, 00:00

  • Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population

    Mar 1, 2008, 00:00

  • Cost-Utility of Repeated Screening for Chlamydia Trachomatis

    Mar 1, 2008, 00:00

  • Drug Safety Surveillance in China and Other Countries- A Review and Comparison

    Mar 1, 2008, 00:00

  • Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low–Middle-Income Country- A Case Study

    Mar 1, 2008, 00:00

  • Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy

    Mar 1, 2008, 00:00

  • Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program

    Mar 1, 2008, 00:00

  • Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure in Taiwan- Is It Cost Effective?

    Mar 1, 2008, 00:00

  • Evaluation of New Measures of the Impact of Hypothyroidism on Quality of Life and Symptoms- The ThyDQoL and ThySRQ

    Mar 1, 2008, 00:00

  • Statistical Comments

    Mar 1, 2008, 00:00

  • Statistical Comments Are Unfounded

    Mar 1, 2008, 00:00

  • Emerging Health Economics and Outcomes Research in the Asia-Pacific Region

    Mar 1, 2008, 00:00

  • Cost-Effectiveness of Motivational Interviewing for Smoking Cessation and Relapse Prevention among Low-Income Pregnant Women- A Randomized Controlled Trial

    Mar 1, 2008, 00:00

  • System Dynamic Modeling- An Alternative Method for Budgeting

    Mar 1, 2008, 00:00

  • Drug Control and Formulary Management in Malaysia

    Mar 1, 2008, 00:00

  • Health-Care Delivery System and Reimbursement Policies in Pakistan

    Mar 1, 2008, 00:00

  • Health-Care Systems and Pharmacoeconomic Research in Asia-Pacific Region

    Mar 1, 2008, 00:00

  • HBeAg-Negative Chronic Hepatitis B- Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan

    Mar 1, 2008, 00:00

  • Migraine Frequency and Health Utilities- Findings from a Multisite Survey

    Mar 1, 2008, 00:00

  • A Multinational Investigation of Time and Traveling Costs in Attending Anticoagulation Clinics

    Mar 1, 2008, 00:00

  • Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies- A Study in a Multiethnic Asian Population in Singapore

    Mar 1, 2008, 00:00

  • Cost-Utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, P.R. China

    Mar 1, 2008, 00:00

  • Evidence-Based Decision-Making and Health Technology Assessment in South Korea

    Mar 1, 2008, 00:00

  • A Cost Function Analysis of Shigellosis in Thailand

    Mar 1, 2008, 00:00

  • Comparing the Standard EQ-5D Three-Level System with a Five-Level Version

    Mar 1, 2008, 00:00

  • The Association of Body Mass Index with Health-Related Quality of Life- An Exploratory Study in a Multiethnic Asian Population

    Mar 1, 2008, 00:00

  • Advanced Cutaneous Malignant Melanoma- A Systematic Review of Economic and Quality-of-Life Studies

    Mar 1, 2008, 00:00

  • Ten-Year Survival and Cost Following Breast Cancer Recurrence- Estimates from SEER-Medicare Data

    Mar 1, 2008, 00:00

  • Gaussian Process Metamodeling in Bayesian Value of Information Analysis- A Case of the Complex Health Economic Model for Breast Cancer Screening

    Mar 1, 2008, 00:00

  • Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk- Results of the Hong Kong Hospital Audit Study

    Mar 1, 2008, 00:00

  • Estimating the Cost of Complications of Diabetes in Australia Using Administrative Health-Care Data

    Mar 1, 2008, 00:00

  • Issues in Drug Pricing, Reimbursement, and Access in China with References to Other Asia-Pacific Region

    Mar 1, 2008, 00:00

  • Evidence-Based Medicine in China

    Mar 1, 2008, 00:00

  • The Reliability and Validity of a Korean Translation of the BASDAI in Korean Patients with Ankylosing Spondylitis

    Mar 1, 2008, 00:00

  • Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand

    Mar 1, 2008, 00:00

  • Economic Evaluations of Smoking Cessation and Relapse Prevention Programs for Pregnant Women- A Systematic Review

    Mar 1, 2008, 00:00

  • Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis- Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program

    Jan 1, 2008, 00:00

  • Cost-Effectiveness of Pemetrexed Plus Cisplatin- Malignant Pleural Mesothelioma Treatment in UK Clinical Practice

    Jan 1, 2008, 00:00

  • Private Demand for Cholera Vaccines in Hue, Vietnam

    Jan 1, 2008, 00:00

  • Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States- An Adjunctive Treatment for Type 2 Diabetes Mellitus

    Jan 1, 2008, 00:00

  • Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease

    Jan 1, 2008, 00:00

  • Cost-of-Illness Studies in the United States- A Systematic Review of Methodologies Used for Direct Cost

    Jan 1, 2008, 00:00

  • Are N-of-1 Trials an Economically Viable Option to Improve Access to Selected High Cost Medications? The Australian Experience

    Jan 1, 2008, 00:00

  • Better Pharmaceutical Price Comparison Studies Are Needed for Meaningful Evaluation of Price-Control Policies

    Jan 1, 2008, 00:00

  • The Impact of Medical Technology on Health- A Longitudinal Analysis of Ischemic Heart Disease

    Jan 1, 2008, 00:00

  • Estimates of Costs of Hospital Stay for Variceal and Nonvariceal Upper Gastrointestinal Bleeding in the United States

    Jan 1, 2008, 00:00

  • Health State Utilities- A Framework for Studying the Gap Between the Imagined and the Real

    Jan 1, 2008, 00:00

  • The Impact of Atypical Antipsychotic Medications on the Use of Health Care by Patients with Schizophrenia

    Jan 1, 2008, 00:00

  • Medication Compliance and Persistence- Terminology and Definitions

    Jan 1, 2008, 00:00

  • Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population

    Jan 1, 2008, 00:00

  • PAR7 COST EFFECTIVENESS OF AUTOANTIBODIES AGAINST CYCLIC CITRULLINATED PEPTIDE IN THE VERY EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PMH8 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA- 3 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CANADA

    Nov 1, 2007, 00:00

  • PCN9 COST-EFFECTIVENESS OF SUPERFICIAL BLADDER CANCER SURVEILLANCE IN WHICH CYSTOSCOPY IS PARTLY REPLACED BY MICROSATELLITE ANALYSIS

    Nov 1, 2007, 00:00

  • MD2 ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PAR33 OSWESTRY HIP SCORE- A PATIENT ASSESSED TOOLTO MEASURE HIP FUNCTION

    Nov 1, 2007, 00:00

  • PDB49 ESTIMATE OF HEALTH CARE RESOURCES NEEDED TO INITIATE INSULIN—RELATIVE COSTS OF DIFFERENT OPTIONS IN UK CLINICAL PRACTICE

    Nov 1, 2007, 00:00

  • PCN59 TREATMENT PATTERNS FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) IN GERMANY

    Nov 1, 2007, 00:00

  • POS9 COMPARATIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TERIPARATIDE [RHPTH(l-34)] VERSUS RHPTH(l-84)

    Nov 1, 2007, 00:00

  • PEY11 ESTIMATING NET HEALTH BENEFITS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)

    Nov 1, 2007, 00:00

  • PCN41 HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT- AN ECONOMIC MODEL OF THE IMPACT ON HEALTH CARE COSTS IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCN8 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)- THE ITALIAN CASE

    Nov 1, 2007, 00:00

  • PDB50 UTILIZING OF CLAIMS DATABASES FOR IMPROVEMENT OF PRESCRIPTION HABITS FOR DIABETES MELLITUSTYPE 2

    Nov 1, 2007, 00:00

  • PMC1 COMPARISON OF EMR DATA TO US NATIONAL DATA

    Nov 1, 2007, 00:00

  • PHP34 EXAMINING INCENTIVES FOR SUBGROUPING IN NICE SUBMISSIONS

    Nov 1, 2007, 00:00

  • CV5 FONDAPARINUX (FOND) VERSUS ENOXAPARIN (ENOX) FOR PREVENTION ANDTREATMENT OFVENOUS THROMBOEMBOLIC EVENTS (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY OF THE LOWER LIMBS (MOSLL) IN GERMANY- ECONOMIC EVALUATION FROMTHE HOSPITAL PE ...

    Nov 1, 2007, 00:00

  • PCN50 COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY

    Nov 1, 2007, 00:00

  • PCV80 PERSISTENCE AND ADHERENCE TO HYPOLIPEMIC THERAPY IN REAL PRACTICE- RESULTS OF A LARGE ADMINISTRATIVE DATABASE

    Nov 1, 2007, 00:00

  • PDB61 VALIDATING THE EXTERNAL VALIDITY OF RANDOMIZED CONTROLLED TRAILS WITH OBSERVATIONAL STUDIES AND CAUSAL EFFECT METHODS (PROPENSITY SCORE, MARGINAL STRUCTURE MODEL AND DOUBLY ROBUST METHODS)

    Nov 1, 2007, 00:00

  • CV3 DO DIFFERENCES IN DOSE IMPACT ADHERENCE TO SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS 2-PILL AMLODIPINE AND ATORVASTATIN?

    Nov 1, 2007, 00:00

  • PAA18 USING CLAIMS DATA TO MODELTHE BUDGETARY IMPACT OF A NEW TREATMENT FOR RHINITIS

    Nov 1, 2007, 00:00

  • PHP4 CANADIAN COMPETION DURING A U.S. GENERIC DRUG'S 180-DAY EXCLUSIVITY PERIOD

    Nov 1, 2007, 00:00

  • PIN43 ADAPTATION OF A HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER IN A WELL FUNCTIONING POPULATION-BASED SCREENING SYSTEM—A MODEL CALIBRATION TO FINLAND

    Nov 1, 2007, 00:00

  • PDB14 2-YEAR GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS NPH INSULIN IN INDIVIDUALS WITHTYPE 2 DIABETES (T2DM)

    Nov 1, 2007, 00:00

  • PHM16 PHARMACOKINETIC-PHARMACODYNAMIC-PHARMACOECONOMIC (P3) MODELING TO INFORM PHARMACOGENOMIC TRIAL DESIGN AND RISK MANAGEMENT

    Nov 1, 2007, 00:00

  • PHM7 COST SIMULATION OF NOVOSEVEN VERSUS FEIBAAND ITT-F8 FOR PRIMARY PROPHYLAXIS TREATMENT OF HAEMOPHILIA A/B PATIENTS WITH INHIBITORS

    Nov 1, 2007, 00:00

  • PDB45 THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND DIABETES-RELATED COSTS- EVIDENCE FROM A CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PAA15 EFFECT OF IMMUNOTHERAPY ON DRUG USE AND COST IN RAGWEED POLLEN ALLERGIC DISEASE IN LOMBARDIA

    Nov 1, 2007, 00:00

  • Denouement- A Patient-Reported Observation

    Nov 1, 2007, 00:00

  • PCV89 THE IMPACT OF COMMUNITY HEALTH WORKER INTERVENTION ON DISEASE MANAGEMENT AND QUALITY OF LIFE OF HIGH RISK POPULATION WITH CHRONIC DISEASE- EXPERIENCE IN BALTIMORE, MD, USA

    Nov 1, 2007, 00:00

  • PAR15 IMPACT OF CO-MORBIDITY BURDEN ON REALWORLD HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS INITIATING ANTI-TUMOR NECROSIS FACTOR THERAPY

    Nov 1, 2007, 00:00

  • PUK13 COST OF DIALYSIS IN A UK SETTING—A MULTICENTRE MICROCOSTING STUDY

    Nov 1, 2007, 00:00

  • PAA16 A RETROSPECTIVE STUDY COMPARING TREATMENT PATTERNS, OUTCOMES, AND RESOURCE USE BETWEEN TWO FIXED COMBINATIONS OF INHALED CORTICOSTEROIDSAND LONG-ACTING B2-AGONIST (ICS/LABA) IN ASTHMATIC PATIENTS IN GERMANY

    Nov 1, 2007, 00:00

  • PDB39 IMPACT OF HBAIC IN TYPE 2 DIABETES MELLITUS IN MEXICO- SIMULATION ANALYSIS, A PHARMACOECONOMIC PERSPECTIVE

    Nov 1, 2007, 00:00

  • PAR13 ANNUAL TREATMENT COSTS OF PATIENTS WITH RHEUMATOID ARTHRITISWITH METOTREXATE AND LEFLUNOMIDE IN SPAIN

    Nov 1, 2007, 00:00

  • PRS14 THE IMPACT OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION ON QUALITY OF LIFE OF ASTHMA AND COPD PATIENTS

    Nov 1, 2007, 00:00

  • PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFATHERAPY IN HUNGARY

    Nov 1, 2007, 00:00

  • RS2 RESOURCE USE AND FINANCIAL IMPACT OF CRITICALLY ILL PATIENTS WITH PNEUMONIA AND RESPIRATORY FAILURE IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PCV24 COST EFFECTIVENESS OF THE CARDIOVASCULAR PREVENTION WITH RAMIPRIL AND/OR STATINS IN HIGH RISK POPULATION IN ITALY

    Nov 1, 2007, 00:00

  • PMH48 IMPACT OF COMORBIDITY ON EQ-5D-A STUDY OF HEALTH-RELATED QUALITY OF LIFE IN DEPRESSION IN A GENERAL POPULATION SURVEY

    Nov 1, 2007, 00:00

  • PAA5 CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/ FORMOTEROL INHALER FORTREATMENT OF BRONCHIAL ASTHMA

    Nov 1, 2007, 00:00

  • PCN6 HOSPITALIZATION COSTS FORTWO METHODS OFTSH STIMULATION DURING THE RADIOIODINE ABLATION IN THYROID CANCER PATIENTS

    Nov 1, 2007, 00:00

  • CN1 USING THE FACT-NEUROTOXICITY TO EVALUATE QUALITY OF LIFE IN CANCER PATIENTS FROM ACROSS THE GLOBE

    Nov 1, 2007, 00:00

  • PMC26 UTILITY INDEX CALCULATION- SIMULATION STUDY CONSIDERING THE HEALTH STATUS AFTER AN INTERVENTION

    Nov 1, 2007, 00:00

  • ND4 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN INTHE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND

    Nov 1, 2007, 00:00

  • PCV19 A MODEL-BASED ANALYSIS OF THE EFFECTS OF INTENSIFYING LI PI D-ALTERING THERAPY ON DIRECT MEDICAL COSTS OF CORONARY HEART DISEASE EVENTS IN A SECONDARY PREVENTION POPULATION IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PST1 SEASONAL VARIATION OF TRANSIENT ISCHEMIC ATTACK (TIA) IN HUNGARY

    Nov 1, 2007, 00:00

  • PND39 PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PARKINSON'S DISEASE- OVERVIEW OF US AND EUROPEAN DRUG APPROVALS

    Nov 1, 2007, 00:00

  • PIN20 COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FORTHETREATMENT OF HERPES ZOSTER IN SPAIN

    Nov 1, 2007, 00:00

  • PMC22 THE TURKISH WEIGHTING OF THE EUROQOL

    Nov 1, 2007, 00:00

  • PDB58 CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PDB2 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) PATIENTS WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) AS ADD-ONTHERAPY

    Nov 1, 2007, 00:00

  • PCN5 THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL

    Nov 1, 2007, 00:00

  • PMH45 THE IMPACT OF CHANGES IN ANTIDEPRESSANT DRUG TREATMENT IN ELDERLY NURSING HOME (NH) PATIENTS—AREAS OF POTENTIAL CARE DETERIORATION DUE TO FORMULARY POLICIES- RESULTS FROM A PILOT STUDY

    Nov 1, 2007, 00:00

  • PDB15 LOWER RATE OF HOSPITALIZATION IN SUBSEQUENTYEAR OF INSULIN GLARGINE VS NPH INITIATION IN INDIVIDUALS WITHTYPE 2 DIABETES (T2DM)

    Nov 1, 2007, 00:00

  • PMH36 A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST CURRENT STIMULANT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY

    Nov 1, 2007, 00:00

  • PCN40 HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT- AN ECONOMIC MODEL OF THE IMPACT ON GERMAN HEALTH CARE COSTS

    Nov 1, 2007, 00:00

  • PUK17 ENDOSCOPIO INJECTION VERSUS ANTIBIOTIC PROPHYLAXIS IN THE REDUCTION OF URINARYTRACT INFECTIONS IN PATIENTS WITH VESICOURETERAL REFLUX

    Nov 1, 2007, 00:00

  • PCN26 INNOVATION OVERTHE PRODUCT LIFE CYCLE- ESTIMATING THE POTENTIAL ECONOMIC VALUE OF TRASTUZUMAB IN BREAST CANCER IN FIVE EUROPEAN COUNTRIES BETWEEN 2000 AND 2020

    Nov 1, 2007, 00:00

  • PND4 DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH TREATMENTS OF NEUROLOGICAL DISORDERS

    Nov 1, 2007, 00:00

  • PND37 A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS

    Nov 1, 2007, 00:00

  • PDB21 COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OFYOUNGER PATIENTS WITH NEWLY DIAGNOSEDTYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2007, 00:00

  • PCN43 COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER

    Nov 1, 2007, 00:00

  • PRS17 SELECTION OF UTILITY INSTRUMENTS FORASTHMAAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2007, 00:00

  • PCN31 COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IVAS FIRST LINE THERAPY FORADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PND23 A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-IA

    Nov 1, 2007, 00:00

  • PCN23 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN ITALY

    Nov 1, 2007, 00:00

  • PCN14 COST-EFFECTIVENESS OF EXEMESTANEVS, TAMOXIFEN IN POST-MENOPAUSALWOMEN WITH EARLY BREAST CANCER IN GERMANY

    Nov 1, 2007, 00:00

  • PIN34 PREDICTORS OF COSTS FOR SKIN AND SKIN STRUCTURE INFECTIONS DUE TO ST/IPH/LOCOCCUS/IUREUS USING A MANAGED-CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PSM3 AN EVALUATION OF THE COST-EFFECTIVENESS OF AN EXTENDED COURSE OF VARENICLINE IN PREVENTING SMOKERS WHO HAVE QUIT FROM RELAPSING

    Nov 1, 2007, 00:00

  • PAA7 A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL IMMUNOTHERAPY COMPARED TO SUBCUTANEOUS IMMUNOTHERAPY IN THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS

    Nov 1, 2007, 00:00

  • POB4 GEMCAS MODEL—A DECISION ANALYTIC MODEL ASSESSING THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESITY AND ASSOCIATED CARDIOVASCULAR RISK FACTORS

    Nov 1, 2007, 00:00

  • PMH34 A PHARMACOECONOMIC OUTCOMES ANALYSIS COMPARING RISPERIDONE LONG-ACTING INJECTION AND CONVENTIONAL DEPOT ANTIPSYCHOTICS

    Nov 1, 2007, 00:00

  • PCV36 COST-EFFECTIVENESS OF THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA WITH A PREVENTIVE TREATMENT ATORVASTATIN-BASED

    Nov 1, 2007, 00:00

  • PDB63 ESTIMATING THE LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN ASPART (NOVORAPID®) FROM HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE POLISH SETTING

    Nov 1, 2007, 00:00

  • PMH55 DEVELOPMENT AND VALIDATION OF THE SLEEP IMPACT SCALE FOR INSOMNIA

    Nov 1, 2007, 00:00

  • PIN37 COST-UTILITY OF ALFAPEGINTERFERON-2A (40 KD) IN CO-INFECTED PATIENTS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    Nov 1, 2007, 00:00

  • PDB5 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

    Nov 1, 2007, 00:00

  • PDB66 RETROSPECTIVE COMPARISON OF COMPLIANCE TO FIXED-DOSE COMBINATION VERSUS SINGLE AGENT COMBINATION THERAPY FOR THE TREATMENT OF DIABETES

    Nov 1, 2007, 00:00

  • PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY

    Nov 1, 2007, 00:00

  • PSK12 PATIENT REPORTED OUTCOMES IN PSORIASIS

    Nov 1, 2007, 00:00

  • PDB59 METHODOLOGICAL APPROACH ASSESSING AN ASSOCIATION OF THE SURROGATE PARAMETER BETA-CELL ACTIVITY AND PATIENT-RELEVANT OUTCOMES IN TYPE 2 DIABETIC PATIENTS

    Nov 1, 2007, 00:00

  • PDB26 COSTS AND NEONATAL OUTCOMES AFTER INSULIN ASPART COMPARED WITH HUMAN INSULIN IN PREGNANTWOMEN WITHTYPE 1 DIABETES

    Nov 1, 2007, 00:00

  • PCN74 PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING- ADAPTATION OF A QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PG14 ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA

    Nov 1, 2007, 00:00

  • PHM17 RECOMBINANT ACTIVATED FACTOR VII (RFVIIA)VS. ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) FOR ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS WITH INHIBITORS- A SYSTEMATIC REVIEW AND BAYESIAN META-REGRESSION SURVIVAL MODEL WIT ...

    Nov 1, 2007, 00:00

  • PCV79 PERSISTENCE TO ANTILIPIDEMICS VARIES BY SEX, AGE, AND RACE/ETHNICITY- ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PND22 MILD TO MODERATE ALZHEIMER'S DISEASE ASSOCIATED WITH SIGNIFICANT TIME BURDEN TO CAREGIVERS

    Nov 1, 2007, 00:00

  • PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS

    Nov 1, 2007, 00:00

  • PHP11 EFFICIENCY IN DRUG PRESCRIPTION MEASURED BYTHE APPLICATION OF ADJUSTED CLINICAL GROUPS IN FIVE SPANISH PRIMARY CARE CENTRES

    Nov 1, 2007, 00:00

  • PPN10 LINGUISTIC ADAPTATION INTO SPANISH AND PSYCHOMETRIC VALIDATION OF THE NEUROPATHIC PAIN SCREENING QUESTIONNAIRE- ID PAIN

    Nov 1, 2007, 00:00

  • PCN49 COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL

    Nov 1, 2007, 00:00

  • PCV67 MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION (STEMI) ACCORDING TO GUIDELINES IN SPAIN

    Nov 1, 2007, 00:00

  • PCV76 MEASUREMENT OF FRACTIONAL FLOW RESERVE IN PATIENTS WITH CORONARY ARTERY DISEASE TO GUIDE TREATMENT—RESULTS FROM A HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYTIC MODEL

    Nov 1, 2007, 00:00

  • PIN41 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE ECONOMIC BURDEN OF FEBRILE NEUTROPENIA

    Nov 1, 2007, 00:00

  • PIH2 RISK-ADJUSTED MALNUTRITION STATUS AS PREDICTOR FOR CLINICAL OUTCOMES IN HOSPITALIZED PATIENTS (RAMP)

    Nov 1, 2007, 00:00

  • PMC11 DEALING WITH COMPETING CAUSES OF DEATH, ILLNESS AND COSTS-THE DISEASE ELIMINATION LIFE TABLE ANALYSIS (DELTA) MODEL

    Nov 1, 2007, 00:00

  • PSK13 PSYCHOMETRIC VALIDATION OF THE OILY SKIN SELF ASSESSMENT SCALE (OSSAS) AND THE OILY SKIN IMPACT SCALE (OSIS)

    Nov 1, 2007, 00:00

  • PCV48 MAJOR BLEED RESOURCE USE AND COSTS FOR PATIENTS HOSPITALISED WITH ACUTE CORONARY SYNDROME IN FRANCE, ITALY. AND SPAIN

    Nov 1, 2007, 00:00

  • PCN54 INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS- CZECH REPUBLIC LONG-TERM DATA

    Nov 1, 2007, 00:00

  • PCV74 A COMPARATIVE PHARMACOECONOMIC ANALYSIS OF STATINS IN RUSSIA

    Nov 1, 2007, 00:00

  • PAA4 COST-EFFECTIVENESS ANALYSIS OF OMALIZUMABVS STANDARD THERAPY (ST), IN THE MANAGEMENT OF SEVERE ASHTMA

    Nov 1, 2007, 00:00

  • PSU3 THE EFFECTS OF LAPAROSCOPIC SURGERY AND NOSOCOMIAL INFECTIONS ON THE COST OF CARE- EVIDENCE FROM THREE SURGICAL PROCEDURES

    Nov 1, 2007, 00:00

  • PCV61 INDICATOR OF CARDIOVASCULAR MEDICINES USAGE IN PUBLIC PHARMACY CHAIN BELGRADE

    Nov 1, 2007, 00:00

  • POS7 COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • Patient-Reported Outcome Instrument Selection- Designing a Measurement Strategy

    Nov 1, 2007, 00:00

  • PND5 USE OF HEALTH CARE RESOURCES AND CORRESPONDING COSTS IN NEUROLOGICAL DISORDERS IN THE PRIMARY CARE SETTING

    Nov 1, 2007, 00:00

  • PND2 BUDGET IMPACT ANALYSIS OF LEVETIRACETAM ADJUNCTIVE THERAPY IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY IN SCOTLAND

    Nov 1, 2007, 00:00

  • PMC17 ACCOUNTING FOR INITIAL HEALTH STATUS IN MEASURING THE BENEFITS OF HEALTH CARE TECHNOLOGIES

    Nov 1, 2007, 00:00

  • PGI27 ESTIMATION OF WEIGHTS FOR THE SPANISH VERSION OF SF-6DTO DERIVE SOCIETAL HEALTH STATE VALUES USING THE SPANISH VERSION OF SF-36VI

    Nov 1, 2007, 00:00

  • PMH43 POTENTIAL DRUG-DRUG INTERACTIONS WITH RISPERIDONE AND THE RISK OF DISCONTINUATION- A RETROSPECTIVE ANALYSIS OF PATIENTS IN QUEBEC, CANADA

    Nov 1, 2007, 00:00

  • PEY8 A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • PHM8 COST-MINIMIZATION ANALYIS OF DARBEPOETIN-α VERSUS EPOETIN-β IN DIALYSED PATIENTS- A LONG-TERM RETROSPECTIVE MONOCENTRIC ITALIAN STUDY

    Nov 1, 2007, 00:00

  • PST3 STROKE SURVIVORS' CHANGE IN HEALTH RELATED QUALITY OF LIFE OVERTIME AS MEASURED BYTHE STROKE IMPACT SCALE

    Nov 1, 2007, 00:00

  • PND15 THE COST-UTILITY OF EXELON PATCH IN THE MANAGEMENT OF PATIENTS WITH MODERATE ALZHEIMER'S DISEASE IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB37 MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS

    Nov 1, 2007, 00:00

  • PCV54 ATTAINMENT OF LDL CHOLESTEROL GOALS AMONG HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)- HOW LARGE WAS THE GAP BETWEEN EUROPE THE UNITED STATES (US) IN 2006?

    Nov 1, 2007, 00:00

  • PDB48 A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES

    Nov 1, 2007, 00:00

  • PSU5 SYSTEMATIC REVIEW OF PATIENT REPORTED OUTCOMES FOLLOWING INTRADISCAL ELECTROTHERMAL THERAPY (IDET) OR SPINAL FUSION FOR DISCOGENIC LOW BACK PAIN

    Nov 1, 2007, 00:00

  • PCN60 IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD

    Nov 1, 2007, 00:00

  • PDB76 TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROLAND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AG ...

    Nov 1, 2007, 00:00

  • ES7 ASSESSMENT OF LONG-RUN ECONOMIC BENEFITS ASSOCIATED WITH IN-VITRO FERTILIZATION (IVF) FUNDING DECISIONS-A SIMPLIFIED LIFETIME TAX CALCULATION

    Nov 1, 2007, 00:00

  • PHM1 ASSESSING PATIENTS' RISKS OF BLOOD TRANSFUSIONS- A LITERATURE REVIEW OF PUBLISHED INCIDENCE RATES

    Nov 1, 2007, 00:00

  • PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS

    Nov 1, 2007, 00:00

  • PHM11 COST UTILITY OF KNEE SURGERYWITH RECOMBINANT ACTIVATED FACTORVII (RFVIIA) IN HEMOPHILIA PATIENTS WITH INHIBITORS- AN EXPLORATORY MODEL

    Nov 1, 2007, 00:00

  • POS13 IMPACT OF THE ALLOWABLE GAP ON PERSISTENCE IN THE BISPHOSPHONATE MARKET

    Nov 1, 2007, 00:00

  • EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

    Nov 1, 2007, 00:00

  • PMC29 ESTIMATING THE BUDGET IMPACT OF NEWTECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH BENEFITS IN ISRAEL- STAKEHOLDERS' INCENTIVES FOR ADOPTING A RISK-SHARING MECHANISM

    Nov 1, 2007, 00:00

  • PMC12 DRUG ADMINISTRATION SERVICES- AN INFUSION STAGE MODEL IN A MULTI-SITE STUDY OF U.S. PHYSICIAN OFFICES

    Nov 1, 2007, 00:00

  • PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION- A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes to Support Medical Product Labeling Claims- FDA Perspective

    Nov 1, 2007, 00:00

  • PMC16 SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION

    Nov 1, 2007, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159 (current)
  • 160
  • »